专利检索 ipc:"C07D215/44" 第 1 页

1.

发明授权
Tetrahydroquinoline-based bromodomain inhibitors 有权

公开(公告)号：US11787768B2

公开(公告)日：2023-10-17

申请号：US17192683

申请日：2021-03-04

申请人： St. Jude Children's Research Hospital

发明人： R. Kip Guy , P Jake Slavish , William Robert Shadrick , Brandon M. Young , Vincent A. Boyd , Nagakumar Bharatham , Jeanine E. Price , Anang Shelat

IPC分类号： C07D215/42 , C07D215/44 , C07D215/46 , C07D401/10 , C07D401/12 , C07D405/10 , C07D405/12 , C07D409/10 , C07D413/12

CPC分类号： C07D215/42 , C07D215/44 , C07D215/46 , C07D401/10 , C07D401/12 , C07D405/10 , C07D405/12 , C07D409/10 , C07D413/12

摘要： In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

2.

发明公开
ENPP1 MODULATORS AND USES THEREOF 审中-公开

公开(公告)号：US20230183188A1

公开(公告)日：2023-06-15

申请号：US17988575

申请日：2022-11-16

申请人： Vir Biotechnology, Inc.

发明人： Roland D. SAITO , Winston C. TSE

IPC分类号： C07D239/94 , C07D471/04 , C07D215/44 , C07D215/54 , C07D215/233 , C07D405/12 , C07D401/12 , C07D413/12 , C07D417/12

CPC分类号： C07D239/94 , C07D471/04 , C07D215/44 , C07D215/54 , C07D215/233 , C07D405/12 , C07D401/12 , C07D413/12 , C07D417/12

摘要： The disclosure provides compositions and methods of quinoline, quinazolines, and pyrydylpyridines derivatives for the inhibition of ENPP1 modulators.

3.

发明申请
NITROGEN-CONTAINING COMPOUND, ELECTRONIC COMPONENT USING SAME AND ELECTRONIC DEVICE 有权

公开(公告)号：US20230139393A1

公开(公告)日：2023-05-04

申请号：US17789557

申请日：2021-04-08

申请人： Shaanxi Lighte Optoelectronics Material Co., Ltd.

发明人： Jian LI , Tiantian MA , Chao YU

IPC分类号： C07D211/54 , H01L51/00 , C07D213/74 , C07C255/42 , C07D215/44 , C07D239/42 , C07D213/38 , C07F7/08 , C07D409/12 , C07D333/76 , C07D307/91 , C07D405/12 , C07D209/82 , C07D471/04 , C07D401/12 , H01L51/50 , H01L51/42

摘要： The present disclosure belongs to the field of organic electroluminescent materials, and specifically relates to a nitrogen-containing compound, an electronic component using the nitrogen-containing compound and an electronic device using the nitrogen-containing compound. The nitrogen-containing compound has a structure as shown in Formula 1. When the nitrogen-containing compound of the present disclosure is used in an organic electroluminescent device, properties of the device can be effectively improved.

4.

发明申请
2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS 有权

公开(公告)号：US20230040299A1

公开(公告)日：2023-02-09

申请号：US17895273

申请日：2022-08-25

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

发明人： Dominique Amans , Stephen John Atkinson , Lee Andrew Harrison , David Jonathan Hirst , Robert Peter Law , Matthew Lindon , Alexander Preston , Jonathan Thomas Seal , Christopher Roland Wellaway

IPC分类号： A61K31/506 , C07D401/14 , C07D405/14 , C07D413/14 , C07D215/227 , C07D215/46 , C07D215/48 , C07D401/04 , C07D401/12 , C07D405/04 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/08 , C07D498/04 , A61P29/00 , A61P37/00 , A61P31/12 , A61P35/00 , C07D215/44 , A61K31/4375 , A61K31/4706 , A61K31/4709 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/5386 , C07D498/08

摘要： The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.

5.

发明申请
QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 有权

公开(公告)号：US20210276956A1

公开(公告)日：2021-09-09

申请号：US17330279

申请日：2021-05-25

申请人： University of South Carolina , Senex Biotechnology, Inc.

发明人： Igor Roninson , Campbell McInnes , Mengqian Chen , Li Zhang , Jing Li

IPC分类号： C07D215/48 , C07D215/233 , C07D215/18 , C07D215/42 , C07D215/44 , A61P35/00 , A61P35/02

摘要： Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

6.

发明申请
COMPOUNDS AND MATRICES FOR USE IN BONE GROWTH AND REPAIR 有权

公开(公告)号：US20210138117A1

公开(公告)日：2021-05-13

申请号：US17136830

申请日：2020-12-29

申请人： Human BioMolecular Research Institute

发明人： John R. Cashman , Daniel R. Ryan , Sigeng Chen

IPC分类号： A61L27/38 , A61L27/12 , C07D215/44 , C07D487/04 , A61K31/519 , A61K33/42 , A61K38/18 , A61K31/4706 , A61K31/12 , A61K45/06 , A61K35/28 , G01N33/50 , A61L27/28 , A61L27/32 , A61L27/42 , A61L27/54 , A61L27/58 , C07C49/248 , C07C49/255 , C07C225/22 , C07C229/40 , C12Q1/6883

摘要： Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

7.

发明授权
Antiviral drug for severe fever with thrombocytopenia syndrome 有权

公开(公告)号：US11001557B2

公开(公告)日：2021-05-11

申请号：US16479081

申请日：2018-01-16

申请人： Kagoshima University , Nobelpharma Co., Ltd.

发明人： Masanori Baba , Masaaki Toyama , Norikazu Sakakibara

IPC分类号： C07D215/44 , A61P31/12 , C07D401/12 , C07D413/12 , C07D417/12

摘要： The present invention pertains to an antiviral drug for severe fever with thrombocytopenia syndrome, which contains a compound represented by formula (I) or a salt thereof, or a solvate of the compound or salt (In the formula, R1 and R2 are the same or different from each other, and each represents a substituted or unsubstituted C1-10 alkyl group, R1 and R2 may form a substituted or unsubstituted 5- or 6-member ring in conjunction with an adjacent nitrogen atom, and X represent a halogen atom.)

8.

发明申请
4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS 审中-公开

公开(公告)号：US20200181089A1

公开(公告)日：2020-06-11

申请号：US16315930

申请日：2017-07-10

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - , CHU DE NICE

发明人： Thierry PASSERON , Rachid BENHIDA , Pascal DAO , Gian Marco DE DONATIS , Anthony MARTIN

IPC分类号： C07D215/44 , C07D413/04 , C07D401/04 , C07D405/04 , A61P35/04

摘要： The present invention relates to a compound of general formula (I): said compound being as defined in claim (1). The invention also relates to a pharmaceutical composition comprising: —a compound of general formula (I) as defined in claim (12) and, —at least one antibody selected from an anti-PD1 antibody, an anti-CTLA4 antibody, an anti-PD-L1 antibody and a mixture of two or more thereof. The invention also relates to a compound of general formula (I) as defined in claim (17) for use in the treatment of cancer, said cancer being preferably selected from melanoma, bladder, kidney, prostate, colon, lung, breast and blood cancer.